https://www.selleckchem.com/pr....oducts/AZD1152-HQPA.
BACKGROUND BTH1677 is a beta-glucan pathogen-associated molecular pattern (PAMP) being evaluated as a novel immunotherapy of cancer. We previously described that the presence of antibodies against beta-glucan (ABA) in serum is necessary for BTH1677 antitumoral activity. We hypothesized that infusion of immunoglobulin can reinstate responses to BTH1677 in individuals with low ABA levels. PATIENTS AND METHODS We report two single-patient studies one in a patient with metastatic colorectal cancer who received BTH1677, combined with tu
Mi piace
Commento
Condividi
